Baudax Bio Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Baudax Bio's earnings have been declining at an average annual rate of -562.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 217.3% per year.

Anahtar bilgiler

-562.2%

Kazanç büyüme oranı

-118.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı217.3%
Özkaynak getirisin/a
Net Marj-4,665.2%
Son Kazanç Güncellemesi30 Sep 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Baudax Bio stock down after pricing $6.2M equity offering

Aug 30

Baudax Bio to get US patent linked to pain drug Anjeso

Aug 22

Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M

Aug 11

Cosette Pharmaceuticals appoints Rick Casten as CFO

Jul 06

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

Sep 09

A First Look At Baudax Bio

May 30

Baudax Bio EPS misses by $0.08, misses on revenue

May 05

Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty

Apr 26

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Feb 17
Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Baudax Bio EPS of $0.62

Nov 09

Baudax Bio: Why I'm Catching This Falling Knife

Nov 03

Gelir ve Gider Dağılımı

Baudax Bio nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

OTCPK:BXRX.Q Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 231-59198
30 Jun 231-61187
31 Mar 231-58196
31 Dec 221-59244
30 Sep 22013243
30 Jun 2210323
31 Mar 221-11403
31 Dec 211-20453
30 Sep 211-66446
30 Jun 211-38477
31 Mar 211-53477
31 Dec 200-76439
30 Sep 200-66387
30 Jun 200-88298
31 Mar 200-692111
31 Dec 190-332317
30 Sep 190-422326
30 Jun 190-512334
31 Mar 190-613138
31 Dec 180-742936

Kaliteli Kazançlar: BXRX.Q is currently unprofitable.

Büyüyen Kar Marjı: BXRX.Q is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: Insufficient data to determine if BXRX.Q's year-on-year earnings growth rate was positive over the past 5 years.

Büyüme Hızlandırma: Unable to compare BXRX.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: BXRX.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Özkaynak Getirisi

Yüksek ROE: BXRX.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin